Celiprolol hydrochloride

Celiprolol hydrochloride is a once-daily, cardioselective β-adrenergic blocker useful in the management of hypertension, angina pectoris and hyperkinetic heart syndrome. It is also being evaluated in glaucoma.

White Crystalline Solid

Chemie Linz (Austria)

antihypertensive antianginal;beta blocker

Cardioselective β1-adrenergic blocker. Antihypertensive, antianginal.

Cardioselective 1-adrenergic blocker. Antihypertensive, antianginal

ChEBI: Celiprolol hydrochloride is an aromatic ketone.

Selecor (Rhone-Poulenc Rorer);SELECTOL.

the ability of celiprolol to induce the regulation of beta adrenergic receptors was investigated in s49 lymphoma cells. results showed that celiprolol did not stimulate adenylate cyclase in membranes from wild-type (wt) s49 cells or induced the sequestration of beta adrenergic receptors on intact cells. moreover, exposure of wt s49 cells to celiprolol led to the loss of around half of the total cellular beta adrenergic receptors [1].

in a previous study, japanese white rabbits underwent 30 min of ischemia and 48 h of reperfusion. celiprolol was administered 20 min before ischemia with or without pretreatment with n(omega)-nitro-l-arginine methylester (l-name) or 5-hydroxydecanoic acid sodium salt (5-hd). results showed that celiprolol could significantly reduce the infarct size dose-dependently. the infarct size-reducing effect of celiprolol was found to be completely blocked by l-name but not by 5-hd. in addition, celiprolol could increase the myocardial interstitial levels of nox and reduce the intensity of myocardium staining [2].

Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: NSAIDs antagonise hypotensive effect.
Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide
Antidepressants: enhanced hypotensive effect with MAOIs.
Antihypertensives; enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
Antimalarials: increased risk of bradycardia with mefloquine.
Antipsychotics enhanced hypotensive effect with phenothiazines
.Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
Cytotoxics: possible increased risk of bradycardia with crizotinib.
Diuretics: enhanced hypotensive effect.
Fingolimod: possibly increased risk of bradycardia.Moxisylyte: possible severe postural hypotension.
Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.

Metabolism of celiprolol is minimal and it is mainly excreted unchanged in the urine (50%) and faeces (50%)

[1] reynolds ee, molinoff pb. down regulation of beta adrenergic receptors in s49 lymphoma cells induced by atypical agonists. j pharmacol exp ther. 1986 dec;239(3):654-60.
[2] chen, x. ,minatoguchi, s.,arai, m., et al. celiprolol, a selective β1-blocker, reduces the infarct size through production of nitric oxide in a rabbit model of myocardial infarction. circulation journal 71(4), 574-579 (2007).
[3] ong kt et al. effect of celiprolol on prevention of cardiovascular events in vascular ehlers-danlos syndrome: a prospective randomised, open, blinded-endpoints trial. lancet. 2010 oct 30;376(9751):1476-84.